Sustained-release theophylline pharmacokinetics in the cat

Publisher Website
Google Scholar
Abstract
Theophylline was administered in a three-way crossover design study to six cats intravenously (Aminophylline USP, Invenex Laboratories, Chargrin Falls, OH) and orally as two sustained-release formulations (Slo-bid Gyrocaps (SB), William H. Rorer, Inc., Fort Washington, PA; Theo-Dur Tablets (TD), Key Pharmaceuticals, Miami, FL). Values were determined for mean residence time (SB = 19.4 .+-. 3.2 h; TD = 15.8 .+-. 4.8 h), mean absorption time (SB = 8.0 .+-. 2.3 h; TD = 4.8 .+-. 2.3 h), absolute bioavailability (SB = 82 .+-. 27%; TD = 76 .+-. 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h). After normalization to a dose of 25 mg/kg, the average peak plasma concentrations were also predicted (SB = 10.5 .+-. 3.4 .mu.g/ml; TD = 14.3 .+-. 6.7 Umg/ml). Slo-bid was predicted to provide the least peak:trough fluctuation in theophylline concetrations. Slo-bid and Theo-Dur appear to have pharmacokinetic characteristics which, if given once-daily, would maintain plasma theophylline concentrations of 5-20 .mu.g/ml in the cat.

This publication has 11 references indexed in Scilit: